ClinicalTrials.gg
TerminatedNCT02468557Updated Apr 2, 2021Results posted

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1 interventional study of Idelalisib and Nab-paclitaxel in Previously Untreated Pancreatic Ductal Adenocarcinoma and Relapsed/Refractory Pancreatic Ductal Adenocarcinoma, sponsored by Gilead Sciences. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-02.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.

02

Conditions studied

  • Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

Browse trials for

03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The presence of pancreatic adenocarcinoma plus 1 of the following:

    • Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR
    • Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin
  • per (RECIST) v1.1
  • Prior systemic chemotherapy treatment for metastatic pancreatic ductal adenocarcinoma (Arm: idelalisib single agent only)
  • Received one for metastatic pancreatic ductal adenocarcinoma (Arm: idelalisib + mFOLFOX6 only)
  • Adequate organ function defined as follows:

    • Hepatic: Total ≤ 1.25 x (ULN) (Arm: idelalisib + nab-paclitaxel ); total bilirubin ≤1.5 x ULN (Arm: single agent idelalisib and Arm: idelalisib + mFOLFOX6); (AST) serum glutamic oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) \< 2.5 x ULN, and albumin > 3.0 g/dL
    • Hematological: (ANC) > 1,500 cells/cubic millimetre (m\^3), > 100,000 cells/mm\^3, > 9.0 grams/decilitre (g/dL)
    • Renal: Serum creatinine ≤ 1.5 x ULN OR calculated (CrCl) > 30 millilitre (ml)/min as calculated by the Cockcroft-Gault method
  • Able to comprehend and willing to sign the written form

Key Exclusion Criteria:

  • Currently or previously treated with biologic, or immunotherapy
  • Currently or previously treated with conventional chemotherapy, or other agents for metastatic pancreatic ductal adenocarcinoma (Arm: idelalisib + nab-paclitaxel only)
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
  • Known human immunodeficiency viruses () infection
  • History of a concurrent or second except for adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to enrollment, adequately treated Stage 1 or 2 non-pancreatic cancer currently in complete remission, or any other non-pancreatic cancer that has been in complete remission for ≥ 5 years
  • Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma (eg, lymphoma, sarcoma), adenocarcinoma originating from the biliary tree or cystadenocarcinoma
  • History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis
  • Presence of peripheral neuropathy ≥ Grade 2 (Arm: idelalisib + nab-paclitaxel and Arm: idelalisib + mFOLFOX6)
  • Documented myocardial infarction or unstable/uncontrolled cardiac disease (eg, unstable angina, congestive heart failure [ > Class III]) within 6 months or enrollment
  • Known to idelalisib, its metabolites, or formulation
  • Known hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipients
  • Known hypersensitivity to 5-fluorouracil, leucovorin, or oxaliplatin (Arm: idelalisib + mFOLFOX6), their metabolites, or formulation excipients

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Idelalisib 150 mg

    Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.

    Drug: Idelalisib

  • Experimental
    Idelalisib + nab-paclitaxel

    Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.

    Drug: Idelalisib · Drug: Nab-paclitaxel

  • Experimental
    Idelalisib + mFOLFOX6

    Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.

    Drug: Idelalisib · Drug: mFOLFOX6

Interventions

  • Tablets administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

  • 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle

  • DrugmFOLFOX6

    mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.

06

What researchers measure

Primary outcomes

  1. Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events (AEs) with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the study drug. It also included the AEs that led to premature discontinuation of study drug.

    Time frame: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days

  2. Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post baseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Severity grade is defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening). The percentage of participants for any post-baseline abnormal laboratory value in the Grade 1-4 category is reported. The term 'hypo' indicates less than the normal count of a parameter and 'hyper' indicates more than the normal count of a parameter.

    Time frame: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days

  3. Idelalisib in Combination With Chemotherapy: Percentage of Participants With Dose Limiting Toxicities (DLTs)

    Dose limiting toxicities were defined as toxicities experienced during the first 28 days of treatment (Cycle 1) that were judged to be clinically significant and at least possibly related to study treatment.

    Time frame: Up to 28 days

Secondary outcomes

  1. Change From Baseline in FoxP3+ and Cluster Determinant 8+ (CD8+) Cells From Tumor Tissue Samples as a Measure of Pharmacodynamics Activity

    Time frame: Up to 2 years

  2. Idelalisib Plasma Concentrations Following Idelalisib 150 mg Twice Daily

    Time frame: Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 hours (h) postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose

  3. Idelalisib Metabolite (GS-563117) Plasma Concentrations Following Idelalisib 150 mg Twice Daily

    Time frame: Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 h postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose

  4. Overall Response Rate (ORR)

    Overall response rate (ORR) was defined as the percentage of participants who achieved a Complete Response (CR) or Partial Response (PR) as assessed by response evaluation criteria in sold tumors (RECIST) v1.1.

    Time frame: Up to 2 years

  5. Overall Survival (OS)

    Overall survival is defined as the interval from first dose date of study drug to death from any cause.

    Time frame: Up to 2 years

  6. Progression Free Survival (PFS)

    Progression free survival is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: Up to 2 years

07

Results

Posted Mar 22, 2021
Limitations and caveats
Due to the early termination of the study, the prespecified efficacy, pharmacodynamic, and pharmacokinetic analysis for PK parameters were not conducted.

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 30 July 2015. The last study visit occurred on 27 April 2016.

Participant flow — Overall Study
MilestoneIdelalisib 150 mg
Started16
Completed0
Not completed16
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Study terminated by sponsor, regulatory agency or institutional review board/ ethics committee10
Withdrew: All enrolled but never dosed4

Outcome measures

PrimarySingle-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events (AEs) with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the study drug. It also included the AEs that led to premature discontinuation of study drug.

Time frame:
First dose date up to last dose date (Maximum: 8 weeks) plus 30 days
Reported as:
Number · percentage of participants
Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsIdelalisib 150 mg
Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)100.0
PrimarySingle-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post baseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Severity grade is defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening). The percentage of participants for any post-baseline abnormal laboratory value in the Grade 1-4 category is reported. The term 'hypo' indicates less than the normal count of a parameter and 'hyper' indicates more than the normal count of a parameter.

Time frame:
First dose date up to last dose date (Maximum: 8 weeks) plus 30 days
Reported as:
Number · percentage of participants
Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities
percentage of participantsIdelalisib 150 mg
Hemoglobin (Hypo), Hematology25.0
Lymphocytes (Hyper), Hematology8.3
Lymphocytes (Hypo), Hematology25.0
Platelets, Hematology8.3
Alanine Aminotransferase, Chemistry58.3
Albumin, Chemistry16.7
Alkaline Phosphatase, Chemistry33.3
Aspartate Aminotransferase, Chemistry66.7
Bilirubin, Chemistry16.7
Creatinine Clearance, Chemistry16.7
Gamma Glutamyl Transferase, Chemistry50.0
Glucose (Hyper), Chemistry16.7
Sodium (Hypo), Chemistry25.0
PrimaryIdelalisib in Combination With Chemotherapy: Percentage of Participants With Dose Limiting Toxicities (DLTs)

Dose limiting toxicities were defined as toxicities experienced during the first 28 days of treatment (Cycle 1) that were judged to be clinically significant and at least possibly related to study treatment.

Time frame:
Up to 28 days

No measurements were reported for this outcome.

SecondaryChange From Baseline in FoxP3+ and Cluster Determinant 8+ (CD8+) Cells From Tumor Tissue Samples as a Measure of Pharmacodynamics Activity
Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryIdelalisib Plasma Concentrations Following Idelalisib 150 mg Twice Daily
Time frame:
Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 hours (h) postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose
Reported as:
Median · ng/mL
Idelalisib Plasma Concentrations Following Idelalisib 150 mg Twice Daily
ng/mLIdelalisib 150 mg
Cycle 1; Day 1 (Predose)NA (NA to NA)
Cycle 1; Day 1 (0.5 h)1110 (13.90 to 3220)
Cycle 1; Day 1 (1 h)1880 (39.10 to 4060)
Cycle 1; Day 1 (1.5 h)1690 (318 to 2260)
Cycle 1; Day 1 (2 h)1290 (173 to 4460)
Cycle 1; Day 1 (3 h)795 (631 to 2870)
Cycle 1; Day 1 (4 h)1540 (519 to 1990)
Cycle 1; Day 1 (8 h)251 (134 to 753)
Cycle 1; Day 8 (Predose)264 (208 to 501.5)
Cycle 1; Day 8 (1.5 h)2050 (1335 to 2620)
Cycle 1; Day 15 (Predose)275 (241 to 1120)
Cycle 1; Day 15 (1.5 h)1605 (1170 to 2130)
Cycle 2; Day 1 (Predose)178.05 (39.05 to 281)
Cycle 2; Day 1 (1.5 h)2180 (1825 to 3095)
SecondaryIdelalisib Metabolite (GS-563117) Plasma Concentrations Following Idelalisib 150 mg Twice Daily
Time frame:
Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 h postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose
Reported as:
Median · ng/mL
Idelalisib Metabolite (GS-563117) Plasma Concentrations Following Idelalisib 150 mg Twice Daily
ng/mLIdelalisib 150 mg
Cycle 1; Day 1 (Predose)NA (NA to NA)
Cycle 1; Day 1 (0.5 h)173 (NA to 220)
Cycle 1; Day 1 (1 h)1220 (16.70 to 1460)
Cycle 1; Day 1 (1.5 h)1070 (141 to 1930)
Cycle 1; Day 1 (2 h)1700 (106 to 4430)
Cycle 1; Day 1 (3 h)1580 (190 to 5980)
Cycle 1; Day 1 (4 h)1370 (849 to 5960)
Cycle 1; Day 1 (8 h)632 (619 to 5340)
Cycle 1; Day 8 (Predose)2175 (1385 to 5790)
Cycle 1; Day 8 (1.5 h)2775 (1765 to 5725)
Cycle 1; Day 15 (Predose)2130 (1020 to 6800)
Cycle 1; Day 15 (1.5 h)2890 (2010 to 4815)
Cycle 2; Day 1 (Predose)1046.5 (490.34 to 1360)
Cycle 2; Day 1 (1.5 h)1405 (1325 to 2305)
SecondaryOverall Response Rate (ORR)

Overall response rate (ORR) was defined as the percentage of participants who achieved a Complete Response (CR) or Partial Response (PR) as assessed by response evaluation criteria in sold tumors (RECIST) v1.1.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival is defined as the interval from first dose date of study drug to death from any cause.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

Progression free survival is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days All-cause mortality: First dose date up to study termination (approximately 39 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib 150 mg2/12 (16.7%)3/12 (25%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventIdelalisib 150 mg
CoagulopathyBlood and lymphatic system disorders1/12
Small intestinal obstructionGastrointestinal disorders1/12
Upper gastrointestinal haemorrhageGastrointestinal disorders1/12
PyrexiaGeneral disorders1/12
Alanine aminotransferase increasedInvestigations1/12
Aspartate aminotransferase increasedInvestigations1/12
DehydrationMetabolism and nutrition disorders1/12
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/12
Acute kidney injuryRenal and urinary disorders1/12
Rash maculo-papularSkin and subcutaneous tissue disorders1/12
Most frequent other events
Showing 10 of 39
Most frequent other events
EventIdelalisib 150 mg
PyrexiaGeneral disorders5/12
Aspartate aminotransferase increasedInvestigations4/12
Alanine aminotransferase increasedInvestigations3/12
Abdominal painGastrointestinal disorders2/12
ConstipationGastrointestinal disorders2/12
VomitingGastrointestinal disorders2/12
ChillsGeneral disorders2/12
InsomniaPsychiatric disorders2/12
HaematuriaRenal and urinary disorders2/12
RashSkin and subcutaneous tissue disorders2/12

Baseline characteristics

The Full Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Idelalisib 150 mg
Mean62 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib 150 mg
Female6
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib 150 mg
Race — American Indian or Alaska Native0
Race — Asian0
Race — Black1
Race — Native Hawaiian or Pacific Islander0
Race — White11
Race — Other0
Race — Not Permitted0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib 150 mg
Ethnicity — Hispanic or Latino0
Ethnicity — Not Hispanic or Latino12
Ethnicity — Not Permitted0
08

Study locations

9 sites
  • Scottsdale Healthcare Clinical Research Institute
    Scottsdale, Arizona 85258, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Indiana University Goshen Center for Cancer Care
    Goshen, Indiana 46506, United States
  • Dana Farber/ Harvard Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75230, United States
09

References and documents

Publications

  • Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J, Rajakumaraswamy N. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov;25(11):e1604-e1613. doi: 10.1634/theoncologist.2020-0321. Epub 2020 Jun 18. PubMed 32356383 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Apr 2016, 8 months.

Results were first posted in Mar 2021, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 11, 2015
StartActual
Jul 30, 2015
Primary completionActual
Apr 27, 2016
CompletionActual
Apr 27, 2016
Results first posted
Mar 22, 2021
Last update
Apr 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02468557
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jul 30, 2015
Primary completion
Apr 27, 2016
Completion
Apr 27, 2016
Results posted
Mar 22, 2021
Last update
Apr 2, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion